Pfizer: Washed-Out And On The Verge Of A Huge Turnaround

1
1
Favorite

Pfizer: Washed-Out And On The Verge Of A Huge Turnaround

Seekingalpha2023-10-18

Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.The company no longer expects a midpoint revenue outlook of $68.5B, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（1）

RedDotter
·2023-10-19
Great ariticle, would you like to share it?
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2376548412?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-18 13:37","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2376548412","market":"us","top_or_hot":-1,"title":"Pfizer: Washed-Out And On The Verge Of A Huge Turnaround","media":"Seekingalpha","content":"<div>\n<p>Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.The company no longer expects a midpoint revenue outlook of $68.5B, ...</p>\n\n<a href=\"https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer: Washed-Out And On The Verge Of A Huge Turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer: Washed-Out And On The Verge Of A Huge Turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-18 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.The company no longer expects a midpoint revenue outlook of $68.5B, ...</p>\n\n<a href=\"https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PFE","symbol_name":"辉瑞","start_time":0,"source_url":"https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround","article_id":"2376548412","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2376548412","pubTimestamp":1697607433,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Management updated investors in a conference call yesterday  as it elaborated on the critical aspects of its COVID franchise and cost-cutting programs. While Pfizer is expected to incur one-time restructuring charges of about $3B, it has also identified cost savings of approximately $3.5B through 2024. In addition, Pfizer expects the Seagen acquisition to be unaffected by the recent guidance change as Pfizer looks to shake off the COVID growth headwinds. Notwithstanding the near-term hit, Pfizer is optimistic about the long-term opportunities for its COVID franchise as it moves into the commercial market. As such, management remains confident about its $30B long-term outlook as Pfizer looks to increase its vaccination rates in line with the annual","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PFE":"辉瑞"},"translate_title":"辉瑞：被淘汰，即将迎来巨大的转机","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1},"content_text":"Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.The company no longer expects a midpoint revenue outlook of $68.5B, downgrading it to between $58B and $61B.Despite the guidance change, Pfizer remains optimistic about the long-term opportunities for its COVID franchise.I assessed that the clarity provided by management is finally in sync with what the market has anticipated, given the hammering in 2023. Pfizer was too optimistic at the start of 2023.With PFE already in washed-out status, I argue why the updated guidance should help PFE bottom out finally, as it didn't collapse below its September lows.I can hardly blame Pfizer Inc. (NYSE: PFE) investors for feeling frustrated. After seeing PFE topping out in December 2022, the market has correctly anticipated that Pfizer could be mired in a substantial COVID growth normalization phase. Notwithstanding management's initial confidence in 2023, Pfizer's recent sharp guidance revision last week justified the market's pessimism. While I remained bullish over PFE, my mean-reversion thesis has yet to play out accordingly, given the COVID revenue uncertainties.Accordingly, Pfizer reduced its FY23 adjusted EPS outlook from a midpoint of $3.35. The revised guidance range between $1.45 and $1.65 suggests a midpoint metric of $1.55, down nearly 54% from its initial midpoint outlook. The company highlighted one-time charges (primarily on inventory write-offs) and a sharp reduction in revenue outlook, leading to a significant revision in its guidance.Accordingly, Pfizer no longer expects a midpoint revenue outlook of $68.5B. The revised revenue outlook is expected to be between $58B and $61B, resulting in a midpoint guidance of $59.5B. Most of these reductions are related to the overstatement of the revenue attribution from its COVID franchise, given the adjustments with the US government.With that in mind, I believe management has sought to clear the air before its upcoming third-quarter or FQ3 earnings release on October 31. It's the right move that could help the \"washed-out\" PFE stock finally form a robust bottoming process for its subsequent recovery. Makes sense?Management updated investors in a conference call yesterday (October 16) as it elaborated on the critical aspects of its COVID franchise and cost-cutting programs.While Pfizer is expected to incur one-time restructuring charges of about $3B, it has also identified cost savings of approximately $3.5B through 2024. In addition, Pfizer expects the Seagen acquisition to be unaffected by the recent guidance change as Pfizer looks to shake off the COVID growth headwinds.Notwithstanding the near-term hit, Pfizer is optimistic about the long-term opportunities for its COVID franchise as it moves into the commercial market. As such, management remains confident about its $30B long-term outlook as Pfizer looks to increase its vaccination rates in line with the annual flu market with COVID-flu combination vaccines.PFE Quant Grades (Seeking Alpha)As seen above, the market has reflected significant pessimism on PFE's valuation, with a \"B\" grade assigned by Seeking Alpha Quant. While it's expected to take a near-term profitability hit in the second half, it helps Pfizer's cost base to potentially bottom out this year and inflect in 2024 after reflecting these one-time charges.While moving toward the commercial market is filled with significant uncertainties, I have confidence in Pfizer's long-term COVID target, providing upside optimism. As such, while the market could remain cautious as Pfizer makes the necessary transition to the commercial scene, peak pessimism is likely reached or even close, given the recent guidance downgrade.PFE price chart (weekly) (TradingView)As seen above, PFE didn't break down below its September lows ($31 level) despite the guidance change last week. As such, it suggests that the market had already anticipated PFE's guidance revision, focusing on its recovery from 2024. Moreover, PFE's price action suggests that a bear trap (false downside breakdown) could happen over the next few months if buyers can defend the current levels robustly.In other words, I gleaned that unless Pfizer still needs to make significant changes to its guidance subsequently, the recent management update should finally be adequate to help its stock bottom out. Investors need clarity to assess the resilience of Pfizer's COVID revenue, and I believe they likely got what they needed over the past week.Rating: Maintain Strong Buy.Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Please always apply independent thinking and note that the rating is not intended to time a specific entry/exit at the point of writing unless otherwise specified.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":232053304586400,"gmtCreate":1697683632078,"gmtModify":1697683635890,"author":{"id":"4095701466603510","authorId":"4095701466603510","name":"RedDotter","avatar":"https://static.itradeup.com/news/0cd781383facbd5189a332ec20374b21","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095701466603510","authorIdStr":"4095701466603510"},"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/232053304586400","repostId":2376548412,"repostType":2,"repost":{"id":"2376548412","pubTimestamp":1697607433,"share":"https://ttm.financial/m/news/2376548412?lang=&edition=fundamental","pubTime":"2023-10-18 13:37","market":"us","language":"en","title":"Pfizer: Washed-Out And On The Verge Of A Huge Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2376548412","media":"Seekingalpha","summary":"Management updated investors in a conference call yesterday  as it elaborated on the critical aspects of its COVID franchise and cost-cutting programs. While Pfizer is expected to incur one-time restructuring charges of about $3B, it has also identified cost savings of approximately $3.5B through 2024. In addition, Pfizer expects the Seagen acquisition to be unaffected by the recent guidance change as Pfizer looks to shake off the COVID growth headwinds. Notwithstanding the near-term hit, Pfizer is optimistic about the long-term opportunities for its COVID franchise as it moves into the commercial market. As such, management remains confident about its $30B long-term outlook as Pfizer looks to increase its vaccination rates in line with the annual","content":"<html><head></head><body><ul style=\"\"><li><p>Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.</p></li><li><p>The company no longer expects a midpoint revenue outlook of $68.5B, downgrading it to between $58B and $61B.</p></li><li><p>Despite the guidance change, Pfizer remains optimistic about the long-term opportunities for its COVID franchise.</p></li><li><p>I assessed that the clarity provided by management is finally in sync with what the market has anticipated, given the hammering in 2023. Pfizer was too optimistic at the start of 2023.</p></li><li><p>With PFE already in washed-out status, I argue why the updated guidance should help PFE bottom out finally, as it didn&#39;t collapse below its September lows.</p></li></ul><p>I can hardly blame Pfizer Inc. (NYSE: PFE) investors for feeling frustrated. After seeing PFE topping out in December 2022, the market has correctly anticipated that Pfizer could be mired in a substantial COVID growth normalization phase. Notwithstanding management&#39;s initial confidence in 2023, Pfizer&#39;s recent sharp guidance revision last week justified the market&#39;s pessimism. While I remained bullish over PFE, my mean-reversion thesis has yet to play out accordingly, given the COVID revenue uncertainties.</p><p>Accordingly, Pfizer reduced its FY23 adjusted EPS outlook from a midpoint of $3.35. The revised guidance range between $1.45 and $1.65 suggests a midpoint metric of $1.55, down nearly 54% from its initial midpoint outlook. The company highlighted one-time charges (primarily on inventory write-offs) and a sharp reduction in revenue outlook, leading to a significant revision in its guidance.</p><p>Accordingly, Pfizer no longer expects a midpoint revenue outlook of $68.5B. The revised revenue outlook is expected to be between $58B and $61B, resulting in a midpoint guidance of $59.5B. Most of these reductions are related to the overstatement of the revenue attribution from its COVID franchise, given the adjustments with the US government.</p><p>With that in mind, I believe management has sought to clear the air before its upcoming third-quarter or FQ3 earnings release on October 31. It&#39;s the right move that could help the &#34;washed-out&#34; PFE stock finally form a robust bottoming process for its subsequent recovery. Makes sense?</p><p>Management updated investors in a conference call yesterday (October 16) as it elaborated on the critical aspects of its COVID franchise and cost-cutting programs.</p><p>While Pfizer is expected to incur one-time restructuring charges of about $3B, it has also identified cost savings of approximately $3.5B through 2024. In addition, Pfizer expects the <a href=\"https://laohu8.com/S/SGEN\">Seagen</a> acquisition to be unaffected by the recent guidance change as Pfizer looks to shake off the COVID growth headwinds.</p><p>Notwithstanding the near-term hit, Pfizer is optimistic about the long-term opportunities for its COVID franchise as it moves into the commercial market. As such, management remains confident about its $30B long-term outlook as Pfizer looks to increase its vaccination rates in line with the annual flu market with COVID-flu combination vaccines.</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/f46f2d8b8300007fc83a981fef51fb7e\" tg-width=\"430\" tg-height=\"307\"/></p><p>PFE Quant Grades (Seeking Alpha)</p><p>As seen above, the market has reflected significant pessimism on PFE&#39;s valuation, with a &#34;B&#34; grade assigned by Seeking Alpha Quant. While it&#39;s expected to take a near-term profitability hit in the second half, it helps Pfizer&#39;s cost base to potentially bottom out this year and inflect in 2024 after reflecting these one-time charges.</p><p>While moving toward the commercial market is filled with significant uncertainties, I have confidence in Pfizer&#39;s long-term COVID target, providing upside optimism. As such, while the market could remain cautious as Pfizer makes the necessary transition to the commercial scene, peak pessimism is likely reached or even close, given the recent guidance downgrade.</p><p></p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/a0b6cb6ce074b5bd1d60b370755f1fe8\" tg-width=\"640\" tg-height=\"339\"/></p><p>PFE price chart (weekly) (TradingView)</p><p>As seen above, PFE didn&#39;t break down below its September lows ($31 level) despite the guidance change last week. As such, it suggests that the market had already anticipated PFE&#39;s guidance revision, focusing on its recovery from 2024. Moreover, PFE&#39;s price action suggests that a bear trap (false downside breakdown) could happen over the next few months if buyers can defend the current levels robustly.</p><p>In other words, I gleaned that unless Pfizer still needs to make significant changes to its guidance subsequently, the recent management update should finally be adequate to help its stock bottom out. Investors need clarity to assess the resilience of Pfizer&#39;s COVID revenue, and I believe they likely got what they needed over the past week.</p><p><em>Rating: Maintain Strong Buy.</em></p><p><em>Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Please always apply independent thinking and note that the rating is not intended to time a specific entry/exit at the point of writing unless otherwise specified.</em></p></body></html>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer: Washed-Out And On The Verge Of A Huge Turnaround</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer: Washed-Out And On The Verge Of A Huge Turnaround\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-18 13:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround><strong>Seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.The company no longer expects a midpoint revenue outlook of $68.5B, ...</p>\n\n<a href=\"https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://seekingalpha.com/article/4641233-pfizer-washed-out-and-on-the-verge-of-a-huge-turnaround","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"2376548412","content_text":"Pfizer slashed its FY23 adjusted EPS outlook by nearly 54% due to one-time charges and a sharp reduction in revenue outlook.The company no longer expects a midpoint revenue outlook of $68.5B, downgrading it to between $58B and $61B.Despite the guidance change, Pfizer remains optimistic about the long-term opportunities for its COVID franchise.I assessed that the clarity provided by management is finally in sync with what the market has anticipated, given the hammering in 2023. Pfizer was too optimistic at the start of 2023.With PFE already in washed-out status, I argue why the updated guidance should help PFE bottom out finally, as it didn't collapse below its September lows.I can hardly blame Pfizer Inc. (NYSE: PFE) investors for feeling frustrated. After seeing PFE topping out in December 2022, the market has correctly anticipated that Pfizer could be mired in a substantial COVID growth normalization phase. Notwithstanding management's initial confidence in 2023, Pfizer's recent sharp guidance revision last week justified the market's pessimism. While I remained bullish over PFE, my mean-reversion thesis has yet to play out accordingly, given the COVID revenue uncertainties.Accordingly, Pfizer reduced its FY23 adjusted EPS outlook from a midpoint of $3.35. The revised guidance range between $1.45 and $1.65 suggests a midpoint metric of $1.55, down nearly 54% from its initial midpoint outlook. The company highlighted one-time charges (primarily on inventory write-offs) and a sharp reduction in revenue outlook, leading to a significant revision in its guidance.Accordingly, Pfizer no longer expects a midpoint revenue outlook of $68.5B. The revised revenue outlook is expected to be between $58B and $61B, resulting in a midpoint guidance of $59.5B. Most of these reductions are related to the overstatement of the revenue attribution from its COVID franchise, given the adjustments with the US government.With that in mind, I believe management has sought to clear the air before its upcoming third-quarter or FQ3 earnings release on October 31. It's the right move that could help the \"washed-out\" PFE stock finally form a robust bottoming process for its subsequent recovery. Makes sense?Management updated investors in a conference call yesterday (October 16) as it elaborated on the critical aspects of its COVID franchise and cost-cutting programs.While Pfizer is expected to incur one-time restructuring charges of about $3B, it has also identified cost savings of approximately $3.5B through 2024. In addition, Pfizer expects the Seagen acquisition to be unaffected by the recent guidance change as Pfizer looks to shake off the COVID growth headwinds.Notwithstanding the near-term hit, Pfizer is optimistic about the long-term opportunities for its COVID franchise as it moves into the commercial market. As such, management remains confident about its $30B long-term outlook as Pfizer looks to increase its vaccination rates in line with the annual flu market with COVID-flu combination vaccines.PFE Quant Grades (Seeking Alpha)As seen above, the market has reflected significant pessimism on PFE's valuation, with a \"B\" grade assigned by Seeking Alpha Quant. While it's expected to take a near-term profitability hit in the second half, it helps Pfizer's cost base to potentially bottom out this year and inflect in 2024 after reflecting these one-time charges.While moving toward the commercial market is filled with significant uncertainties, I have confidence in Pfizer's long-term COVID target, providing upside optimism. As such, while the market could remain cautious as Pfizer makes the necessary transition to the commercial scene, peak pessimism is likely reached or even close, given the recent guidance downgrade.PFE price chart (weekly) (TradingView)As seen above, PFE didn't break down below its September lows ($31 level) despite the guidance change last week. As such, it suggests that the market had already anticipated PFE's guidance revision, focusing on its recovery from 2024. Moreover, PFE's price action suggests that a bear trap (false downside breakdown) could happen over the next few months if buyers can defend the current levels robustly.In other words, I gleaned that unless Pfizer still needs to make significant changes to its guidance subsequently, the recent management update should finally be adequate to help its stock bottom out. Investors need clarity to assess the resilience of Pfizer's COVID revenue, and I believe they likely got what they needed over the past week.Rating: Maintain Strong Buy.Important note: Investors are reminded to do their due diligence and not rely on the information provided as financial advice. Please always apply independent thinking and note that the rating is not intended to time a specific entry/exit at the point of writing unless otherwise specified.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}